» Articles » PMID: 30498085

TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib

Overview
Journal Cancer Res
Specialty Oncology
Date 2018 Dec 1
PMID 30498085
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic lymphocytic leukemia (CLL) is a malignancy of mature B cells driven by B-cell receptor (BCR) signaling and activated primarily in the lymph node. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib effectively inhibits BCR-dependent proliferation and survival signals and has emerged as a breakthrough therapy for CLL. However, complete remissions are uncommon and are achieved only after years of continuous therapy. We hypothesized that other signaling pathways that sustain CLL cell survival are only partially inhibited by ibrutinib. In normal B cells, Toll-like receptor (TLR) signaling cooperates with BCR signaling to activate prosurvival NF-κB. Here, we show that an experimentally validated gene signature of TLR activation is overexpressed in lymph node-resident CLL cells compared with cells in the blood. Consistent with TLR activation, we detected phosphorylation of NF-κB, STAT1, and STAT3 in lymph node-resident CLL cells and in cells stimulated with CpG oligonucleotides . CpG promoted IRAK1 degradation, secretion of IL10, and extended survival of CLL cells in culture. CpG-induced TLR signaling was significantly inhibited by both an IRAK1/4 inhibitor and ibrutinib. Although inhibition of TLR signaling was incomplete with either drug, the combination achieved superior results, including more effective inhibition of TLR-mediated survival signaling. Our data suggest an important role for TLR signaling in CLL pathogenesis and in sustaining the viability of CLL cells during ibrutinib therapy. The combination of ibrutinib with a TLR pathway inhibitor could provide superior antitumor activity and should be investigated in clinical studies. SIGNIFICANCE: CLL relies on the concomitant cooperation of B-cell receptor and Toll-like receptor signaling; inhibition of both pathways is superior to inhibition of either pathway alone. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/2/360/F1.large.jpg.

Citing Articles

IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.

Luo Y, Su B, Hung V, Luo Y, Shi Y, Wang G Proc Natl Acad Sci U S A. 2024; 121(33):e2405644121.

PMID: 39121163 PMC: 11331101. DOI: 10.1073/pnas.2405644121.


Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.

Pozzo F, Forestieri G, Vit F, Ianna G, Tissino E, Bittolo T Leukemia. 2024; 38(8):1712-1721.

PMID: 38914716 PMC: 11286529. DOI: 10.1038/s41375-024-02301-y.


Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death.

Mantione M, Meloni M, Sana I, Bordini J, Del Nero M, Riba M Cell Death Dis. 2024; 15(3):224.

PMID: 38494482 PMC: 10944843. DOI: 10.1038/s41419-024-06602-z.


Identification of the Axis β-Catenin-BTK in the Dynamic Adhesion of Chronic Lymphocytic Leukemia Cells to Their Microenvironment.

Mihoub I, Rharass T, Ouriemmi S, Oudar A, Aubard L, Gratio V Int J Mol Sci. 2023; 24(24).

PMID: 38139452 PMC: 10744074. DOI: 10.3390/ijms242417623.


Toll-like receptor 9 signaling in chronic lymphocytic leukemia cell lines.

Meloni M, Sana I, Mantione M, Riba M, Muzio M FEBS Open Bio. 2023; 13(12):2367-2374.

PMID: 37881888 PMC: 10699106. DOI: 10.1002/2211-5463.13726.


References
1.
Krutzik P, Nolan G . Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A. 2003; 55(2):61-70. DOI: 10.1002/cyto.a.10072. View

2.
Bagnara D, Kaufman M, Calissano C, Marsilio S, Patten P, Simone R . A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011; 117(20):5463-72. PMC: 3109718. DOI: 10.1182/blood-2010-12-324210. View

3.
Kipps T, Stevenson F, Wu C, Croce C, Packham G, Wierda W . Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017; 3:16096. PMC: 5336551. DOI: 10.1038/nrdp.2016.96. View

4.
Herman S, Wiestner A . Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade. Semin Oncol. 2016; 43(2):222-32. PMC: 4856050. DOI: 10.1053/j.seminoncol.2016.02.007. View

5.
Hanna B, McClanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rossner P . Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia. 2015; 30(3):570-9. DOI: 10.1038/leu.2015.305. View